Vasogen Inc.

Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure

    Mississauga, Canada (ots/PRNewswire) - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) and Grupo Ferrer Internacional, S.A.  ("Ferrer"), a leading European  pharmaceutical and medical devices company,  today announced the receipt of initial orders for Vasogen's Celacade(TM) System in Germany. Celacade, a first-in-class therapy, is the only CE Mark  approved product that specifically targets the destructive chronic  inflammation underlying the development and progression of chronic heart  failure. Under the CE Mark, Celacade can be marketed in the 27 countries that  comprise the European Union and is indicated in the EU for the treatment of  New York Heart Association (NYHA) Class II patients and NYHA Class II, III, &  IV heart failure patients who do not have a prior history of heart attack.

    In the international ACCLAIM trial, Celacade was shown to significantly  reduce the risk of death or cardiovascular hospitalizations in large  pre-specified subgroups of patients with chronic heart failure, including  NYHA Class II patients, where risk was reduced by 39%, and NYHA Class II to  IV patients with no prior heart attack, where risk was reduced by 26%. The  commercial introduction of Celacade in the European Union provides physicians and patients with a novel approach for the treatment of heart failure that is  safe and well tolerated and can be used in combination with currently  approved therapies for this condition.

    "The initial orders for the Celacade System are a major milestone for  Vasogen," commented Chris Waddick, President and CEO of Vasogen. "We are  extremely pleased that Ferrer has secured these orders so quickly after  completing key pre-marketing activities. We look forward to continuing our  close collaboration with Ferrer as we work to rapidly expand the use of  Celacade within the European Union."

    "We are firmly committed to the success of Celacade in Europe," commented Dr. Carlos de Lecea, Vice President International and Business  Development at Ferrer. "We are very pleased that the initial orders are from  sites who participated in the ACCLAIM study, which we believe reflects the  clinical benefits of Celacade and the feedback the physicians received from  patients."

    About Celacade:

    The Celacade System targets the inflammation underlying chronic heart  failure and other cardiovascular diseases. Inflammation is a normal response  of the immune system to cellular injury caused by infection, trauma, or other  stimuli. During the inflammatory process, immune cells release a number of  factors, including cytokines - potent chemical messengers that modulate  inflammation and facilitate the healing process. While this inflammatory  process is usually self-limiting, it can persist, become chronic, and lead to a number of serious medical conditions.

    During a brief outpatient procedure, a small sample of a patient's blood is drawn into Vasogen's Celacade single-use disposable cartridge and  exposed to controlled oxidative stress utilizing Vasogen's proprietary  Celacade medical device technology. Oxidative stress is a factor known to  initiate apoptosis, a physiologic process that is inherently  anti-inflammatory. The treated blood is then administered to the same patient  intramuscularly. An initial course of treatment comprising three consecutive  outpatient procedures is administered over a two-week period, and treatments are continued once per month thereafter.

    About Grupo Ferrer Internacional, S.A.:

    Vasogen has entered into a collaboration with Grupo Ferrer Internacional, a privately held European research and commercial development  based pharmacochemical and medical devices company headquartered in  Barcelona, Spain. Ferrer operates today in over 60 countries with the overall  aim to improve people's health and quality of life. Based on its policy of  continuous expansion throughout the world, Ferrer has established strong  industrial and commercial operations in Europe and has extensive commercial experience in Latin America, Africa, and in the Middle and Far East. Ferrer  has licensing, distribution, and marketing agreements with large  multinational pharmaceutical companies, as well as mid-size firms, including  AstraZeneca, Astellas, Johnson & Johnson, Merck Sharp & Dohme, Novartis,  Roche, Sanofi-Aventis, Solvay, Cephalon, United Therapeutics, and The  Medicines Co., among others. In addition to its commercial operations, Ferrer  operates pharmaceutical research and development facilities in Barcelona, Spain and Alsdorf, Germany. The research facilities in Barcelona manage all  aspects of drug development from concept through to clinical development and  product registration. The Alsdorf facility is specialized in new applications  of pharmaceutical technology. Ferrer also has established research  collaborations with a large number of pharmaceutical companies and  universities throughout the world.

    About Vasogen:

    Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive  inflammatory process associated with the development and progression of  cardiovascular and neurodegenerative disorders. The Company's lead product,  the Celacade System, is designed to activate the immune response to  apoptosis - an important physiological process that regulates inflammation.  Celacade is in late-stage development for the treatment of chronic heart  failure and has received European regulatory approval under the CE Mark for  this indication. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug  candidate from this new class.

    Certain statements contained in this press release or elsewhere in our  public documents constitute "forward-looking statements" within the meaning  of the United States Private Securities Litigation Reform Act of 1995 and/or  "forward-looking information" under the Securities Act (Ontario). These  statements may include, without limitation, plans to advance the development  of Celacade(TM) or VP025, plans to fund our current activities, statements  concerning our partnering activities, health regulatory submissions,  strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements  by terminology such as "may", "will", "should", "expects", "plans",  "anticipates", "believes", "estimated", "predicts", "potential", "continue",  "intends", "could", or the negative of such terms or other comparable  terminology. We made a number of assumptions in the preparation of these  forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart  failure, particularly in Europe, the regulatory approval process leading to  commercialization and the availability of capital on acceptable terms to  pursue the development of Celacade, and the feasibility of additional trials.  You should not place undue reliance on our forward-looking statements which  are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those  projected. These risks include, but are not limited to, the outcome of  further ongoing analysis of the ACCLAIM trial results, the requirement or  election to conduct additional clinical trials and the size and design of any  such trials, delays or setbacks in the regulatory approval process,  difficulties in the maintenance of existing regulatory approvals, securing  and maintaining corporate alliances, the need for additional capital and the  effect of capital market conditions and other factors on capital  availability, the potential dilutive effects of any financing, risks  associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical  trials, competition, market acceptance of our products, the availability of  government and insurance reimbursements for our products, the strength of  intellectual property, reliance on partners, subcontractors, and key  personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and  other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other  securities regulatory bodies. Additional risks and uncertainties relating to  our Company and our business can be found in the "Risk Factors" section of  our Annual Information Form and Form 20-F for the year ended November 30,  2006, as well as in our later public filings. The forward-looking statements  are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise  any forward-looking statements, whether as a result of new information,  future events or otherwise.

    http://www.vasogen.com

ots Originaltext: Vasogen Inc
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
For further information: Glenn Neumann, Investor Relations, 2505
Meadowvale Blvd., Mississauga, ON, Canada L5N 5S2; Tel:
+1-905-817-2004; Fax: +1-905-569-9231;  investor@vasogen.com



Das könnte Sie auch interessieren: